Call for Late-Breaking Abstracts for ObesityWeek® 2026
The Call for Late-Breaking Abstracts will be open June 29 – July 15, 2026.
Decision notifications will be emailed around September 8 from [email protected]. Accepted abstracts will be presented in person in Washington, DC, on November 14, 15, 16, or 17, 2026. Please plan for potential presentation times Saturday through Tuesday. The submission fee for late-breaking abstracts is $130.
If you require an extension for submitting a Late-Breaking Abstract, please review the Late-Breaking Abstract Extension Policy.
Abstract Requirements
- Please refer to these 2026 Abstract Submission Instructions before submitting your Abstract.
- Maximum length: 3,000 characters
- Optional image: PNG only, maximum 3 × 3 inches, 300–600 dpi
If Your Abstract Is Accepted:
- You will receive an email notification from [email protected]
- Confirm your participation using the link provided in the acceptance email
- Complete the required forms via the link provided within the acceptance email
- Review the Speaker Resource Center for next steps and guidance
ObesityWeek® 2026
CALL FOR LATE-BREAKING ABSTRACTS
Submit Your Research:
June 29 – July 15, 2026
Give your research maximum visibility and impact by presenting at ObesityWeek 2026
Did you submit already?
If you submitted an abstract to the March 16 – April 27, 2026 Call for Abstracts, decision notifications will be sent by email around July 9 from [email protected]. Accepted abstracts will be presented in person in Washington, DC, on November 14, 15, 16, or 17, 2026. Please plan for potential presentation times Saturday through Tuesday.
Judging Criteria
Reviewers will be assessing the quality of abstracts based on the following criteria:
Significance
- How meaningful and novel the data are to obesity research and treatment
- Whether the purpose or hypothesis is clearly stated and appropriate
- The contribution to practice, research, theory, or knowledge
Methodology
- Quality of the study design, experimental methods, and analytical approach
- Appropriateness of statistical methods
Results
- Clarity and adequacy of results
- Inclusion of appropriate values, whether or not statistical significance is claimed
(For all abstracts except study-design descriptions, program descriptions, or case reports)
Conclusion
- Whether the conclusions are supported by the results
- Clear statement of whether the study’s hypothesis or purpose was validated
- Absence of commercial bias
Corporate Sub-Track Abstract Submission
Presenters submitting on behalf of a corporation must select the Corporate Sub-track on the abstract submission form. Oral presentations within this sub-track are routed to non-CME oral sessions to comply with ACCME requirements, and all posters (which are non-CME) will be labeled with this sub-track.
This requirement applies to all abstracts presented by or on behalf of ACCME-defined ineligible companies. This includes:
- Full-time or part-time employees of an ineligible company
- Individuals working with a communications or marketing firm hired by a medical or pharmaceutical company
- Anyone whose presentation content was created, shaped, or influenced by an ineligible company or its agents
NOTE: This requirement does not apply to university-based PIs whose research was supported by grants. These grant relationships must be disclosed, but do not prevent acceptance into a standard CME oral session.
NOTE: Submitting to the Corporate Sub-track does not affect the likelihood of being selected for an oral presentation.
When using the Submit Abstract Form, toggle the ‘Yes – Corporate Sub-track’ option. See image here.
